...
me-img

23Andme Holding Co, Common Stock

ME

NAQ

$3.27

+$0.21

(6.86%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$79.92M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
290.23K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.26
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.65 L
$19.34 H
$3.27

About 23Andme Holding Co, Common Stock

23andMe Holding Co. operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally. The company operates in two segments, Consumer and Research Services, and Therapeutics. The Consumer and Research Services segment provides personal genome service (PGS) that consists of a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the development of novel therapies; and research and development of programs in various therapeutic areas, such as oncology, immunological and inflammatory diseases, and other disease areas, as well as engages in the out-licensing of intellectual property associated with identified drug targets and expenses related to the discovery and development of therapeutic product candidates. This segment also comprises a therapeutics product portfolio, including 23ME-00610 (P006), a humanized monoclonal antibody that interfere with the ability of CD200R1 to interact with CD200 in cancer cells; GSK6097608, an immuno-oncology program for targeting CD96; and 23ME-01473 is an immuno-oncology antibody program that targets the ULBP6 proteins in the NKG2D pathway. 23andMe Holding Co. was founded in 2006 and is headquartered in South San Francisco, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameMESectorS&P500
1-Week Return-2.39%-2.12%-3%
1-Month Return3.81%-3.42%-0.73%
3-Month Return-51.91%-11.13%2.87%
6-Month Return-60.86%-5.74%7.17%
1-Year Return-81.47%3.97%25.31%
3-Year Return-97.53%1.05%28.38%
5-Year Return-98.33%34.37%81.89%

Financials

Mar '20Mar '21Mar '22Mar '23Mar '245YR TREND
Total Revenue305.46M243.92M271.89M299.49M219.64M[{"date":"2020-03-31","value":100,"profit":true},{"date":"2021-03-31","value":79.85,"profit":true},{"date":"2022-03-31","value":89.01,"profit":true},{"date":"2023-03-31","value":98.04,"profit":true},{"date":"2024-03-31","value":71.9,"profit":true}]
Cost of Revenue168.03M126.91M138.95M164.99M120.26M[{"date":"2020-03-31","value":100,"profit":true},{"date":"2021-03-31","value":75.53,"profit":true},{"date":"2022-03-31","value":82.69,"profit":true},{"date":"2023-03-31","value":98.19,"profit":true},{"date":"2024-03-31","value":71.57,"profit":true}]
Gross Profit137.43M117.01M132.94M134.50M99.38M[{"date":"2020-03-31","value":100,"profit":true},{"date":"2021-03-31","value":85.14,"profit":true},{"date":"2022-03-31","value":96.74,"profit":true},{"date":"2023-03-31","value":97.86,"profit":true},{"date":"2024-03-31","value":72.31,"profit":true}]
Gross Margin44.99%47.97%48.90%44.91%45.25%[{"date":"2020-03-31","value":92.01,"profit":true},{"date":"2021-03-31","value":98.1,"profit":true},{"date":"2022-03-31","value":100,"profit":true},{"date":"2023-03-31","value":91.84,"profit":true},{"date":"2024-03-31","value":92.53,"profit":true}]
Operating Expenses351.19M302.20M387.10M458.51M420.73M[{"date":"2020-03-31","value":76.59,"profit":true},{"date":"2021-03-31","value":65.91,"profit":true},{"date":"2022-03-31","value":84.43,"profit":true},{"date":"2023-03-31","value":100,"profit":true},{"date":"2024-03-31","value":91.76,"profit":true}]
Operating Income(213.75M)(185.20M)(254.15M)(324.01M)(321.36M)[{"date":"2020-03-31","value":-21375500000,"profit":false},{"date":"2021-03-31","value":-18519600000,"profit":false},{"date":"2022-03-31","value":-25415300000,"profit":false},{"date":"2023-03-31","value":-32401100000,"profit":false},{"date":"2024-03-31","value":-32135600000,"profit":false}]
Total Non-Operating Income/Expense(30.86M)3.15M33.46M19.26M(330.94M)[{"date":"2020-03-31","value":-92.24,"profit":false},{"date":"2021-03-31","value":9.43,"profit":true},{"date":"2022-03-31","value":100,"profit":true},{"date":"2023-03-31","value":57.56,"profit":true},{"date":"2024-03-31","value":-989.07,"profit":false}]
Pre-Tax Income(250.86M)(183.62M)(220.97M)(314.43M)(666.63M)[{"date":"2020-03-31","value":-25086300000,"profit":false},{"date":"2021-03-31","value":-18361900000,"profit":false},{"date":"2022-03-31","value":-22097000000,"profit":false},{"date":"2023-03-31","value":-31442800000,"profit":false},{"date":"2024-03-31","value":-66663100000,"profit":false}]
Income Taxes38.45M(255.00K)(3.48M)(2.77M)73.00K[{"date":"2020-03-31","value":100,"profit":true},{"date":"2021-03-31","value":-0.66,"profit":false},{"date":"2022-03-31","value":-9.05,"profit":false},{"date":"2023-03-31","value":-7.21,"profit":false},{"date":"2024-03-31","value":0.19,"profit":true}]
Income After Taxes(289.31M)(183.36M)(217.49M)(311.66M)(666.70M)[{"date":"2020-03-31","value":-28931100000,"profit":false},{"date":"2021-03-31","value":-18336400000,"profit":false},{"date":"2022-03-31","value":-21749000000,"profit":false},{"date":"2023-03-31","value":-31165600000,"profit":false},{"date":"2024-03-31","value":-66670400000,"profit":false}]
Income From Continuous Operations(250.86M)(183.62M)(217.49M)(311.66M)(666.70M)[{"date":"2020-03-31","value":-25086300000,"profit":false},{"date":"2021-03-31","value":-18361900000,"profit":false},{"date":"2022-03-31","value":-21749000000,"profit":false},{"date":"2023-03-31","value":-31165600000,"profit":false},{"date":"2024-03-31","value":-66670400000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":"-","profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}]
Net Income(289.31M)(183.36M)(217.49M)(311.66M)(666.70M)[{"date":"2020-03-31","value":-28931100000,"profit":false},{"date":"2021-03-31","value":-18336400000,"profit":false},{"date":"2022-03-31","value":-21749000000,"profit":false},{"date":"2023-03-31","value":-31165600000,"profit":false},{"date":"2024-03-31","value":-66670400000,"profit":false}]
EPS (Diluted)(0.38)(1.93)(0.70)(0.51)(0.66)[{"date":"2020-03-31","value":-38.23,"profit":false},{"date":"2021-03-31","value":-192.55,"profit":false},{"date":"2022-03-31","value":-70,"profit":false},{"date":"2023-03-31","value":-51,"profit":false},{"date":"2024-03-31","value":-66,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ME
Cash Ratio 0.83
Current Ratio 1.24
Quick Ratio 1.14

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ME
ROA (LTM) -25.77%
ROE (LTM) -154.21%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ME
Debt Ratio Lower is generally better. Negative is bad. 0.68
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.32

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ME
Trailing PE NM
Forward PE NM
P/S (TTM) 0.43
P/B 0.84
Price/FCF NM
EV/R 0.16
EV/Ebitda NM

FAQs

What is 23Andme Holding Co share price today?

23Andme Holding Co (ME) share price today is $3.27

Can Indians buy 23Andme Holding Co shares?

Yes, Indians can buy shares of 23Andme Holding Co (ME) on Vested. To buy 23Andme Holding Co from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ME stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of 23Andme Holding Co be purchased?

Yes, you can purchase fractional shares of 23Andme Holding Co (ME) via the Vested app. You can start investing in 23Andme Holding Co (ME) with a minimum investment of $1.

How to invest in 23Andme Holding Co shares from India?

You can invest in shares of 23Andme Holding Co (ME) via Vested in three simple steps:

  • Click on Sign Up or Invest in ME stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in 23Andme Holding Co shares
What is 23Andme Holding Co 52-week high and low stock price?

The 52-week high price of 23Andme Holding Co (ME) is $19.34. The 52-week low price of 23Andme Holding Co (ME) is $2.65.

What is 23Andme Holding Co price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of 23Andme Holding Co (ME) is

What is 23Andme Holding Co price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of 23Andme Holding Co (ME) is 0.84

What is 23Andme Holding Co dividend yield?

The dividend yield of 23Andme Holding Co (ME) is 0.00%

What is the Market Cap of 23Andme Holding Co?

The market capitalization of 23Andme Holding Co (ME) is $79.92M

What is 23Andme Holding Co’s stock symbol?

The stock symbol (or ticker) of 23Andme Holding Co is ME

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top